{"contentid": 488105, "importid": NaN, "name": "Tecentriq trial hits primary endpoint in lung cancer", "introduction": "Roche has announced that the Phase III IMpower010 study of Tecentriq (atezolizumab) met its primary endpoint of disease-free survival (DFS) at the interim analysis.", "content": "<p>Roche (ROG: SIX) has announced that the Phase III IMpower010 study of Tecentriq (atezolizumab) met its primary endpoint of disease-free survival (DFS) at the interim analysis.</p>\n<p>The Swiss cancer giant is testing its blockbuster checkpoint blocker as an option following surgery and chemo for people with non-small cell lung cancer (NSCLC).</p>\n<p>The statistically-significant benefit was noted in all randomized Stage II-IIIA populations, with a particularly pronounced result in the PD-L1-positive population.</p>\n<p>The firm said that follow-up would continue with planned analyses of DFS in the overall intent-to-treat population, which at the time of analysis did not cross the threshold.</p>\n<p>Overall survival data were also immature at the time of interim analysis.</p>\n<p>Roche said that the data would be submitted to regulatory authorities, including in the USA and in Europe.</p>\n<p>While Tecentriq has not had the same level of impact as leading checkpoint blocker Keytruda (pembrolizumab), developed by Merck &amp; Co (NYSE: MRK), it has become a major revenue driver for the firm.</p>\n<p>Sales grew by 55% in 2020, reaching 2.7 billion Swiss francs ($3 billion).</p>\n<p>Roche has invested heavily in a wide-ranging development program, with multiple ongoing and planned Phase III studies, including in lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers.</p>\n<p>Commenting on the latest trial results, chief medical officer Levi Garraway said: &ldquo;With these landmark results, Tecentriq has become the first cancer immunotherapy to help many people with resectable early lung cancer live longer without their cancer returning.\"</p>\n<p>He added: &ldquo;We&rsquo;re excited by the clinical benefit adjuvant Tecentriq may bring to lung cancer patients, particularly in the PD-L1-positive population. We will submit these data to regulatory authorities as soon as possible.&rdquo;</p>", "date": "2021-03-22 11:28:00", "meta_title": NaN, "meta_keywords": "Tecentriq, cancer, lung, primary, endpoint, analysis, interim, survival, Roche, Phase, trial, hits, atezolizumab, disease-free, study, IMpower, announced", "meta_description": "Roche has announced that the Phase III IMpower010 study of Tecentriq (atezolizumab) met its primary endpoint of disease-free survival (DFS) at the interim analy", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-22 11:27:34", "updated": "2021-03-22 12:13:01", "access": NaN, "url": "https://www.thepharmaletter.com/article/tecentriq-trial-hits-primary-endpoint-in-lung-cancer", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "2020_roche_big.jpg", "image2id": "2020_roche_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology", "topic_tag": "Drug Trial, Research", "geography_tag": "Switzerland", "company_tag": "Roche", "drug_tag": "Tecentriq", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-22 11:28:00"}